Differential Effects of the Oncogenic BRAF Inhibitor PLX4032 (Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function
PURPOSE: The clinically approved oncogenic BRAF inhibitor PLX4032 (vemurafenib) was shown to be a substrate of the ATP-binding cassette (ABC) transporter ABCB1. Here, we compared PLX4032 and its structurally closely related precursor compound PLX4720 for their interference with ABCB1 and the ABCB1-m...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2014-04-01
|
| Reeks: | Journal of Pharmacy & Pharmaceutical Sciences |
| Online toegang: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/20601 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|